A Study of GNTI-122 in Adults Recently Diagnosed With T1D

Recruiting now · Phase 1

Conditions studied: Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus

In brief

This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed T1D. After assessment of eligibility, participants who qualify for the study will be enrolled sequentially in 1 of 3 cohorts. Cohort 1 participants (n=3) receive a low dose of GNTI-122 . Cohort 2 participants (n=3) receive a high dose of GNTI-122. Cohort 3 participants (n=10) receive a high dose of GNTI-122 in combination with rapamycin. Participants are followed for 78 weeks after the administration of GNTI-122 during which safety and efficacy assessments are made, including vital signs, ECG, physical exam, clinical labs, and monitoring of adverse events and concomitant medications. Disease markers (e.g., MMTT-stimulated C-peptide, HbA1c) and pharmacodynamic activity (e.g., lymphocyte subsets and phenotypes, effector T cell responses to islet antigens ex vivo, T1D autoantibodies) will be monitored serially throughout the study. The study will include sentinel dosing and a Safety Review Committee to ensure participant safety. Visit https://www.polarisstudy.com to learn more!

Key facts

Study ID: NCT06919354
Run by: GentiBio, Inc
People needed: 16
Starts: 2025-09-03
Expected to finish: 2028-02-01
Last updated by the study team: 2026-08-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male and female participants aged ≥18 to ≤55 years with recently diagnosed (within 180 days of Screening) T1D according to American Diabetes Association criteria.
Participant has residual β-cell function during Screening, defined as random C-peptide ≥ 0.2 nmol/L.
Positive for at least one T1D-associated autoantibody.
Able and willing to provide written, informed consent as approved by the IRB.
Is confirmed positive for the HLA-DRB1*04:01 allele.
Has adequate vascular access to undergo leukapheresis with no known contraindications.
Female participants of childbearing potential must have a negative serum pregnancy test at Screening, must be not lactating, and must agree to protocol-specified contraception.
Male participants of childbearing potential must agree to protocol specified contraception.
Other than T1D, participant is in good general health.

You may not qualify if…

Type 2 diabetes.
Experienced DKA within 4 weeks prior to or during Screening.
Unwilling or unable to comply with study procedures or schedule.
Chronic or uncontrolled medical condition.
Has another active or autoimmune or inflammatory disease with the exception of well-controlled Hashimoto's thyroiditis, celiac disease, or vitiligo.
Participation in another clinical study or active follow-up in a prior study.

Where it is running

Duke University — Durham, North Carolina, United States (enrolling)
University of California - San Diego — San Diego, California, United States (enrolling)
University of California - San Francisco — San Francisco, California, United States (enrolling)
University of Florida - Gainesville — Gainesville, Florida, United States (enrolling)
University of Miami, Diabetes Research Institute — Miami, Florida, United States (enrolling)
Joslin Diabetes Center — Boston, Massachusetts, United States (enrolling)
Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
City of Hope Medical Center — Duarte, California, United States (enrolling)
University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.